ODI Pharma AB (XSAT:ODI) Total Liabilities: kr8.74 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:ODI ODI Pharma AB XSAT:ODI
46 GF Score
Price kr2.54
GF Value kr9.52
Valuation Significantly Undervalued
View Full Analysis

What is ODI Pharma AB Total Liabilities?

ODI Pharma AB XSAT:ODI +3.25% 46 Total Liabilities is kr8.74 Mil as of Mar. 2026. GuruFocus rates XSAT:ODI with a GF Score™ of 46/100 and a GF Value™ of kr9.52 (Significantly Undervalued).

ODI Pharma AB's Total Liabilities for the quarter that ended in Mar. 2026 was kr8.74 Mil.

ODI Pharma AB's quarterly Total Liabilities increased from Sep. 2025 (kr7.10 Mil) to Dec. 2025 (kr8.00 Mil) and increased from Dec. 2025 (kr8.00 Mil) to Mar. 2026 (kr8.74 Mil).

ODI Pharma AB's annual Total Liabilities increased from Jun. 2023 (kr5.61 Mil) to Jun. 2024 (kr10.23 Mil) but then declined from Jun. 2024 (kr10.23 Mil) to Jun. 2025 (kr4.19 Mil).

ODI Pharma AB Total Liabilities Historical Data

* Premium members only.

The historical data trend for ODI Pharma AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ODI Pharma AB Total Liabilities Chart

ODI Pharma AB Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Liabilities
Get a 7-Day Free Trial 0.58 1.24 5.61 10.23 4.19

ODI Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.53 4.19 7.10 8.00 8.74
XSAT:ODI
46GF Score
ODI Pharma AB XSAT:ODI
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ODI Pharma AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

ODI Pharma AB's Total Liabilities for the fiscal year that ended in Jun. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4.186+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=4.19

Total Liabilities=Total Assets (A: Jun. 2025 )-Total Equity (A: Jun. 2025 )
=4.61-0.425
=4.19

ODI Pharma AB's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=8.737+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=8.74

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=10.527-1.79
=8.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of kr8.74 Mil mean?
ODI Pharma AB (XSAT:ODI) has a Total Liabilities of kr8.74 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for ODI Pharma AB and its competitors.
Is ODI Pharma AB's Total Liabilities too high?
ODI Pharma AB's current Total Liabilities is kr8.74 Mil. Overall, ODI Pharma AB has a GF Score™ of 46/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ODI Pharma AB's Total Liabilities compare to ZTS and UTHR?
ODI Pharma AB's Total Liabilities of kr8.74 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for ODI Pharma AB and its competitors. ODI Pharma AB's current Total Liabilities is kr8.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ODI Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, ODI Pharma AB (XSAT:ODI) is currently considered Significantly Undervalued. The stock's GF Value™ is kr9.52, compared to a current price of kr2.54 — trading 73.3% below its estimated fair value. The current Total Liabilities is kr8.74 Mil. ODI Pharma AB's overall GF Score™ is 46/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For ODI Pharma AB (XSAT:ODI), the current Total Liabilities is kr8.74 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ODI Pharma AB (XSAT:ODI) Overvalued in 2026?

Based on GuruFocus' analysis, ODI Pharma AB stock appears to be undervalued. The current stock price of kr2.54 is trading 73.3% below its estimated GF Value™ of kr9.52. GuruFocus considers ODI Pharma AB to be Significantly Undervalued.

Key valuation signals for XSAT:ODI:

  • Total Liabilities: kr8.74 Mil
  • GF Value™: kr9.52 vs. price of kr2.54 (73.3% below fair value)
  • GF Score™: 46/100

No single metric tells the full story. See the XSAT:ODI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ODI Pharma AB Business Description

Address Ostermalmstorg 1, Stockholm, SWE, 114 42
ODI Pharma AB is a provider of medicinal cannabis. It offers its products to pharmacies, specialty clinics, and hospitals.
46GF Score

Get the complete analysis for XSAT:ODI

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.54
Price
kr9.52
GF Value